← Leaderboards
Keith C Bible
Mayo Clinic Coll Of Medicine, Rochester
$4,335,431
Attributed
$4,945,129
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $643.6K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,945,129 · 5
By mechanism
R01$3,725,733 · 3
P50$1,219,396 · 1
M01$0 · 1
Top collaborators
- Viji Shridhar5 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Jan C Buckner$13,181,861
- William A Cliby$3,264,657
- Lynn C. Hartmann$11,627,700
- Martha Q Lacy$648,671
- Michael J O'Connell$0
Others in their field
Top investigators on “Cytotoxicity”
- David Heimbrook · Leidos Biomedical Research, Inc.$60,494,681
- Philip J Disaia · University Of California Irvine$58,213,103
- Kent J. Weinhold · Duke University$45,381,151
- Brenda J. Weigel · University Of Minnesota$36,792,183
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$34,242,475
- Douglas F Nixon · J. David Gladstone Institutes$30,748,895
Research focus
CytotoxicityResearch StudyInsightMediatingSignal TransductionIn VitroCytotoxicMalignant NeoplasmsCancer Cell LineKillingsBaseSamplingResistanceAnimal ModelFlavopiridolApoptosisTranscription FactorDrug FormulationsBiomarkerMultiple MyelomaGenetic TranscriptionAntineoplasticsCell LineClinical Research
Grant awards (20)
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$219,848
P50 · FY2013 · CA · contact PI
Chaetocin as a Potential Therapy for Multiple Myeloma$346,123
R01 · FY2012 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$238,831
P50 · FY2012 · CA · contact PI
Chaetocin as a Potential Therapy for Multiple Myeloma$349,697
R01 · FY2011 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$233,601
P50 · FY2011 · CA · contact PI
Chaetocin as a Potential Therapy for Multiple Myeloma$368,294
R01 · FY2010 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$248,246
P50 · FY2010 · CA · contact PI
Chaetocin as a Potential Therapy for Multiple Myeloma$364,721
R01 · FY2009 · CA · contact PI
Flavopiridol Reverses Platinum Resistance in Ovarian Cancer$278,870
P50 · FY2009 · CA · contact PI
Chaetocin as a Potential Therapy for Multiple Myeloma$354,669
R01 · FY2008 · CA · contact PI
Flavopiridol Targets Transcription Factor/DNA Complexes$285,494
R01 · FY2006 · CA · contact PI
Flavopiridol Targets Transcription Factor/DNA Complexes$292,365
R01 · FY2005 · CA
Flavopiridol as a Potential Therapy in Multiple Myeloma$259,880
R01 · FY2005 · CA
Flavopiridol Targets Transcription Factor/DNA Complexes$292,365
R01 · FY2004 · CA
Flavopiridol as a Potential Therapy in Multiple Myeloma$259,880
R01 · FY2004 · CA
Flavopiridol Targets Transcription Factor/DNA Complexes$292,365
R01 · FY2003 · CA
Flavopiridol as a Potential Therapy in Multiple Myeloma$259,880
R01 · FY2003 · CA
PHASE I: FLAVOPIRIDOL AND CISPLATIN IN ADVANCED CANCER$0
M01 · FY2002 · RR
PHASE I: FLAVOPIRIDOL AND CISPLATIN IN ADVANCED CANCER$0
M01 · FY2001 · RR
PHASE I: FLAVOPIRIDOL AND CISPLATIN IN ADVANCED CANCER$0
M01 · FY2000 · RR